Shield Therapeutics (LON:STX)‘s stock had its “under review” rating reiterated by Liberum Capital in a report issued on Friday, March 16th.
A number of other analysts also recently weighed in on the company. FinnCap reiterated a “buy” rating and set a GBX 265 ($3.72) target price on shares of Shield Therapeutics in a research report on Tuesday, November 21st. Peel Hunt reiterated a “buy” rating and set a GBX 220 ($3.09) target price on shares of Shield Therapeutics in a research report on Thursday, February 1st.
STX traded up GBX 4 ($0.06) during trading on Friday, hitting GBX 19.50 ($0.27). The stock had a trading volume of 265,219 shares, compared to its average volume of 48,665. Shield Therapeutics has a one year low of GBX 15 ($0.21) and a one year high of GBX 168.50 ($2.37).
ILLEGAL ACTIVITY NOTICE: “Shield Therapeutics (LON:STX) Stock Rating Reaffirmed by Liberum Capital” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/liberum-capital-reaffirms-under-review-rating-for-shield-therapeutics-stx.html.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.